Analysts expect Adma Biologics, Inc. to report revenue of 154.02 M for Q4 26, against a range of 139.68 M to 168.35 M. The most recent reported quarter, Q3 26, came in at 141.10 M, a 3.3% miss against the 145.84 M consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 119.84 M | 117.55 M | 114.80 M | 121.98 M | 134.22 M | 139.16 M | 114.49 M | 124.39 M | 141.10 M | - | - | - | - | - | - | - | - | |||||||||
| High Estimate | 103.22 M | 122.67 M | 119.20 M | 135.13 M | 137.96 M | 155.06 M | 155.04 M | 140.19 M | 152.69 M | 168.35 M | 153.81 M | 156.80 M | 166.10 M | 197.78 M | 168.69 M | 174.01 M | 207.18 M | |||||||||
| Low Estimate | 96.36 M | 111.84 M | 100.70 M | 117.42 M | 119.99 M | 132.12 M | 143.50 M | 126.76 M | 139.00 M | 139.68 M | 136.33 M | 145.81 M | 137.41 M | 166.10 M | 138.68 M | 152.08 M | 182.30 M | |||||||||
| Consensus Estimate | 99.79 M | 117.25 M | 109.95 M | 126.28 M | 128.98 M | 143.59 M | 149.27 M | 133.47 M | 145.84 M | 154.02 M | 145.07 M | 151.30 M | 151.75 M | 181.94 M | 153.68 M | 163.05 M | 194.74 M |
Analysts expect Adma Biologics, Inc. to report earnings per share of 0.23 for Q4 26, against a range of 0.21 to 0.25. The most recent reported quarter, Q3 26, came in at 0.22, a 17.4% beat against the 0.19 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.16 | 0.14 | 0.14 | 0.15 | 0.16 | 0.21 | 0.17 | 0.16 | 0.22 | - | - | - | - | - | - | - | - | |||||||||
| High Estimate | 0.14 | 0.15 | 0.14 | 0.16 | 0.17 | 0.20 | 0.21 | 0.18 | 0.21 | 0.25 | 0.16 | 0.21 | 0.26 | 0.27 | 0.26 | 0.28 | 0.35 | |||||||||
| Low Estimate | 0.12 | 0.13 | 0.14 | 0.14 | 0.15 | 0.18 | 0.19 | 0.16 | 0.17 | 0.21 | 0.16 | 0.17 | 0.22 | 0.25 | 0.24 | 0.26 | 0.31 | |||||||||
| Consensus Estimate | 0.13 | 0.14 | 0.14 | 0.15 | 0.16 | 0.19 | 0.20 | 0.17 | 0.19 | 0.23 | 0.16 | 0.19 | 0.24 | 0.26 | 0.25 | 0.27 | 0.33 |
Pull Wall Street consensus for Adma Biologics, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=ADMA&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "ADMA", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=ADMA&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();